Trials / Completed
CompletedNCT00000863
A Study of WR 6026 in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Patients
A Phase II Study of WR 6026 for Pneumocystis Carinii Pneumonia in People With HIV Infection
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (planned)
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID) · NIH
- Sex
- All
- Age
- 13 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy of WR 6026 once daily in the treatment of mild PCP. To evaluate the safety and tolerance of WR 6026. To assess the correlation between plasma WR 6026 concentrations and outcome/toxicity.
Detailed description
All patients will receive an initial loading dose of WR 6026, followed the next morning and each morning thereafter by 1 of 2 lower doses of WR 6026 taken in a fasting state for 3 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sitamaquine |
Timeline
- Completion
- 1998-07-01
- First posted
- 2001-08-31
- Last updated
- 2021-10-28
Locations
12 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00000863. Inclusion in this directory is not an endorsement.